EBITDA Margin % is calculated as EBITDA divided by its Revenue. Gyre Therapeutics's EBITDA for the
three
months ended in Mar. 2026 was $-6.1 Mil. Gyre Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $22.5 Mil. Therefore, Gyre Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was -27.22%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Gyre Therapeutics EBITDA Margin % Related Terms
Gyre Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Gyre Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GYRE vs CBIO, RIGL, ARVN: EBITDA Margin % Comparison
For the Biotechnology subindustry, Gyre Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gyre Therapeutics (GYRE) has a EBITDA Margin % of -27.22% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gyre Therapeutics and its competitors. Over the past decade, Gyre Therapeutics' EBITDA Margin % has ranged from 4.33 to 35.33. According to the industry distribution chart, Gyre Therapeutics ranks #280 out of 944 companies in the Biotechnology industry, placing it in the top 29.7%.
Is Gyre Therapeutics' EBITDA Margin % too high?
Gyre Therapeutics' current EBITDA Margin % is -27.22%. Over the past 10 years, this metric has ranged from a low of 4.33 to a high of 35.33. Based on the distribution chart, Gyre Therapeutics ranks #280 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Gyre Therapeutics has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' EBITDA Margin % compare to CBIO and RIGL?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #280 out of 944 companies for EBITDA Margin %. This puts Gyre Therapeutics in the upper half of its industry. Historically, Gyre Therapeutics' own EBITDA Margin % has ranged from 4.33 to 35.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gyre Therapeutics and its competitors. Gyre Therapeutics's current EBITDA Margin % is -27.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.82, compared to a current price of $6.30 — trading 35.8% below its estimated fair value. The current EBITDA Margin % is -27.22%. Gyre Therapeutics' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current EBITDA Margin % is -27.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gyre Therapeutics (GYRE) Overvalued in 2026?
Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued.
The current stock price of $6.30 is trading 35.8% below its estimated GF Value™ of $9.82.
GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.
Key valuation signals for GYRE:
EBITDA Margin %: -27.22%
GF Value™: $9.82 vs. price of $6.30 (35.8% below fair value)
No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score
Get the complete analysis for GYRE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GYRE has been successfully added to your 
